A Phase I study of 2-amino-9-B-D-arabinosyl-6-methoxy-9H-purine (506U78) administered on a consecutive five day schedule in children and adults with refractory hematologic malignancies.
Kurtzberg, J; Ernst, TJ; Keating, MJ; Gandhi, V; Hodge, JP; Kisor, DF; Therriault, R; Stephens, C; Levin, J; Krenitsky, T; Elion, GB; Mitchell, BS
Volume / Issue
Start / End Page
International Standard Serial Number (ISSN)